{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:19Z","timestamp":1761058999004},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.medcli.2009.10.013","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T15:10:07Z","timestamp":1261149007000},"page":"70-74","source":"Crossref","is-referenced-by-count":3,"title":["Papel de los bisfosfonatos en el tratamiento adyuvante del c\u00e1ncer de mama"],"prefix":"10.1016","volume":"135","author":[{"given":"Elisa","family":"G\u00e1lvez-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Rodr\u00edguez-Lescure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2009.10.013_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","article-title":"Bisphosphonates: An overview with special reference to alendronate","volume":"38","author":"Vasikaran","year":"2001","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.medcli.2009.10.013_bib2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: Pathogenesis and management","volume":"18","author":"Pfeilschiffer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2009.10.013_bib3","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2009.10.013_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effect of chemotherapy and hormonotherapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2009.10.013_bib5","doi-asserted-by":"crossref","first-page":"s31","DOI":"10.1016\/j.ctrv.2008.03.005","article-title":"Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.medcli.2009.10.013_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisohosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2009.10.013_bib7","first-page":"5","article-title":"Recomendaciones para el uso de bifosfonatos en tumores s\u00f3lidos","volume":"7","author":"G\u00e1lvez Mu\u00f1oz","year":"2008","journal-title":"Met\u00e1stasis \u00d3seas"},{"key":"10.1016\/j.medcli.2009.10.013_bib8","first-page":"26","article-title":"\u00bfQu\u00e9 papel pueden representar los bifosfonatos en el tratamiento adyuvante del c\u00e1ncer de mama?","volume":"23","author":"Guirado","year":"2009","journal-title":"Rev C\u00e1ncer"},{"key":"10.1016\/j.medcli.2009.10.013_bib9","doi-asserted-by":"crossref","first-page":"6301s","DOI":"10.1158\/1078-0432.CCR-06-1211","article-title":"Oral bisphosphonates as adjuvant therapy for operable breast cancer","volume":"12","author":"Powles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2009.10.013_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.medcli.2009.10.013_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonates for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.medcli.2009.10.013_bib12","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.medcli.2009.10.013_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.medcli.2009.10.013_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2009.10.013_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.medcli.2009.10.013_bib16","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.medcli.2009.10.013_bib17","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2009.10.013_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5 year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2009.10.013_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2009.10.013_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.medcli.2009.10.013_bib21","doi-asserted-by":"crossref","first-page":"6309s","DOI":"10.1158\/1078-0432.CCR-06-0652","article-title":"Skeletal complications of breast cancer therapies","volume":"12","author":"Hirbe","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2009.10.013_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2009.10.013_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozol","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.medcli.2009.10.013_bib24","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathological fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2009.10.013_bib25","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B. The number needed to treat (NNT) as a measure of drug efficacy: The case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial. [resumen 2113]. SABCS 2008. Art\u00edculo no publicado. Comunicado en el congreso San Antonio Breast Cancer Symposium 2008. N\u00famero del res\u00famen (ABSTRACT) 2113","DOI":"10.1016\/S0960-9776(09)70187-0"},{"key":"10.1016\/j.medcli.2009.10.013_bib26","doi-asserted-by":"crossref","unstructured":"Winter MC, Thorpe HC. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response. Exploratory evidence for direct anti-tumor activity in breast cancer. Art\u00edculo no publicado. Presentado como resumen en el congreso San Antonio Breast Cancer Symposium 2008, con el n\u00famero 5101. Actualizaci\u00f3n de datos del art\u00edculo: The AZURE trial - does adjuvant zoledronic acid reduce recurrence in patients with high risk localised breast cancer? Burkinshaw R, Thorpe H, Pollard S, Bell R, Codwell D, Cameron D,et al. Bone 2006;38:70-71. [resumen 5101]. SABCS 2008.","DOI":"10.1016\/j.bone.2006.01.017"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775309014602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775309014602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T23:10:47Z","timestamp":1685229047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775309014602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0025775309014602"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2009.10.013","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}